12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vyndaqel tafamidis meglumine regulatory update

FDA issued a complete response letter for an NDA for tafamidis meglumine from Pfizer to treat transthyretin (TTR) familial amyloid polyneuropathy (FAP). According to Pfizer, the agency asked for a second efficacy study and additional information on data included in the NDA. Pfizer said...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >